Diagnostic Role of Circulating miRNAs in the Grading of Chronic Hepatitis B-Related Liver Fibrosis: A Systematic Review and Meta-Analysis.

Laboratory medicine Pub Date : 2023-09-05 DOI:10.1093/labmed/lmac151

Ting Jiang, Wenying Leng, Sen Zhong

{"title":"Diagnostic Role of Circulating miRNAs in the Grading of Chronic Hepatitis B-Related Liver Fibrosis: A Systematic Review and Meta-Analysis.","authors":"Ting Jiang, Wenying Leng, Sen Zhong","doi":"10.1093/labmed/lmac151","DOIUrl":null,"url":null,"abstract":"Objective: miRNAs are considered potential biomarkers that can be used for the grading of chronic hepatitis B (CHB)-related liver fibrosis. This meta-analysis aims to elucidate the diagnostic performance of miRNAs.Methods: Databases were used to search for meta-analyses. A bivariate model was used to calculate pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). In addition, the area under the summary receiver operating characteristic curve (AUC) and 95% confidence intervals (CIs) were calculated.Results: A total of 9 studies with 1159 patients with CHB-related liver fibrosis were assessed. For diagnosis of significant liver fibrosis, the pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.73 (95% CI, 0.68-0.78), 0.78 (95% CI, 0.70-0.84), 3.32 (95% CI, 2.52-4.37), 0.34 (95% CI, 0.30-0.39), 9.70 (95% CI, 7.10-13.24), and 0.81 (95% CI, 0.77-0.84), respectively.Conclusion: miRNAs are potential biomarkers of CHB-related liver fibrosis.","PeriodicalId":17951,"journal":{"name":"Laboratory medicine","volume":"54 5","pages":"479-488"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Laboratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/labmed/lmac151","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Objective: miRNAs are considered potential biomarkers that can be used for the grading of chronic hepatitis B (CHB)-related liver fibrosis. This meta-analysis aims to elucidate the diagnostic performance of miRNAs.

Methods: Databases were used to search for meta-analyses. A bivariate model was used to calculate pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR). In addition, the area under the summary receiver operating characteristic curve (AUC) and 95% confidence intervals (CIs) were calculated.

Results: A total of 9 studies with 1159 patients with CHB-related liver fibrosis were assessed. For diagnosis of significant liver fibrosis, the pooled sensitivity, specificity, PLR, NLR, DOR, and AUC were 0.73 (95% CI, 0.68-0.78), 0.78 (95% CI, 0.70-0.84), 3.32 (95% CI, 2.52-4.37), 0.34 (95% CI, 0.30-0.39), 9.70 (95% CI, 7.10-13.24), and 0.81 (95% CI, 0.77-0.84), respectively.

Conclusion: miRNAs are potential biomarkers of CHB-related liver fibrosis.

查看原文本刊更多论文

循环mirna在慢性乙型肝炎相关肝纤维化分级中的诊断作用:一项系统综述和荟萃分析

目的:mirna被认为是潜在的生物标志物，可用于慢性乙型肝炎(CHB)相关肝纤维化的分级。本荟萃分析旨在阐明mirna的诊断性能。方法:采用数据库进行meta分析。采用双变量模型计算合并敏感性、特异性、阳性似然比(PLR)、阴性似然比(NLR)和诊断优势比(DOR)。此外，还计算了总体受试者工作特征曲线(AUC)下的面积和95%置信区间(ci)。结果:共有9项研究，1159例chb相关肝纤维化患者被评估。对于诊断显著肝纤维化，合并敏感性、特异性、PLR、NLR、DOR和AUC分别为0.73 (95% CI, 0.68-0.78)、0.78 (95% CI, 0.70-0.84)、3.32 (95% CI, 2.52-4.37)、0.34 (95% CI, 0.30-0.39)、9.70 (95% CI, 7.10-13.24)和0.81 (95% CI, 0.77-0.84)。结论:mirna是慢性乙型肝炎相关肝纤维化的潜在生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Laboratory medicine

自引率

0.00%

发文量